We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Contravir Pharmaceuticals (MM) | NASDAQ:CTRV | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.58 | 3.50 | 3.67 | 0 | 01:00:00 |
EDISON, N.J., Nov. 7, 2016 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced that it will present a poster at The Liver Meeting® 2016 held by the American Association for the Study of Liver Diseases (AASLD), taking place November 11-15, 2016, in Boston.
The poster, titled, "Pharmacokinetics, Safety and Antiviral Activity of CMX157, a Novel Prodrug of Tenofovir, Administered as Ascending Multiple Doses to Healthy Volunteers and HBV-Infected Subjects," will provide an overview of recent clinical data supporting CMX157, the company's drug in development for hepatitis B virus (HBV).
Conference Details:
Event: |
The Liver Meeting 2016 | |
Date: |
Monday, November 14, 2016 | |
Session: |
Poster Session IV, "Hepatitis B: Treatment" | |
Poster #: |
1886 | |
Location: |
John B. Haynes Veterans Memorial Convention Center; Boston | |
About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). The Company is developing two novel anti-HBV compounds with complementary mechanisms of action: CMX157, a highly potent analog of the successful antiviral drug tenofovir currently in a Phase 2a clinical trial in HBV patients; and CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. ContraVir is also developing FV-100, an orally available nucleoside analogue prodrug for the treatment of herpes zoster, or shingles, in a Phase 3 clinical trial. In addition to direct antiviral activity, FV-100 previously demonstrated the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN) in a Phase 2 clinical study. For more information visit www.contravir.com.
For further information, please contact:
Sharen Pyatetskaya
Director of Investor Relations
sp@contravir.com; (732) 902-4028
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (investors)
jdrumm@tiberend.com; (212) 375-2664
Claire LaCagnina (media)
clacagnina@tiberend.com; (212) 375-2686
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/contravir-to-present-at-aaslds-the-liver-meeting-2016-300358109.html
SOURCE ContraVir Pharmaceuticals, Inc.
Copyright 2016 PR Newswire
1 Year Contravir Pharmaceuticals Inc Chart |
1 Month Contravir Pharmaceuticals Inc Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions